Tác dụng phụ trên da, móng và chất lượng cuộc sống của người bệnh ung thư phổi không tế bào nhỏ điều trị TKIs tại Bệnh viện Ung Bướu Hà Nội năm 2021-2022=Skin and nail adverse event and quality of life among non-small cell lung cancer patients receiving EGFR-TKI therapy treatment in Hanoi Oncology Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thu Phương Hoàng, Thị Lệ Quyên Lê

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.264-271

Bộ sưu tập: Metadata

ID: 242180

Thêm vào giỏ

Thuốc ức chế Tyrosine Kinase (TKIs) trong điều trị ung thư phổi không tế bào nhỏ (UTPKTBN) giai đoạn tiến xa đã được chứng minh mang lại hiệu quả, cải thiện thời gian sống thêm cho bệnh nhân với đặc điểm dung nạp tốt, mức độ độc tính hạn chế hơn nhiều so với hóa trị. Tuy vậy, liệu pháp này cũng có một số tác dụng phụ, nổi bật là tổn thương tại da và móng. Vì vậy nghiên cứu này nhằm mô tả các tác dụng phụ của TKIs trên da, móng và lượng giá chất lượng cuộc sống của bệnh nhân UTPKTBN có điều trị bằng TKIs. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả, cắt ngang trên 237 bệnh nhân UTPKTBN điều trị TKIs tại Bệnh viện Ung bướu Hà Nội từ 3/2021 -10/2022. Đánh giá tác dụng phụ trên da và móng dựa theo CTCAE 5.0. Chất lượng cuộc sống được tính theo bảng điểm EROTC-QLQ30. Kết quả: Tuổi trung bình là 62,62 ± 10,54, đa số từ 60 tuổi trở lên (67,5%). Viêm da ở bệnh nhân dùng TKIs thế hệ 1, thế hệ 2, thế hệ 3 lần lượt là 98 (55,4%)
40 (80%)
7 (35%). Vị trí viêm da thường gặp nhất là mặt, lưng, đầu. Tỷ lệ gặp viêm móng theo nhóm TKIs thế hệ 1, 2, 3 lần lượt là: 40 (22,6%), 21 (52,5%), 4 (20%). Điểm CLCS của bệnh nhân theo nhóm điều trị TKIs thế hệ 1, thế hệ 2, thế hệ 3 lần lượt là 73,33
77,54
85,43. Kết luận: Tác dụng phụ của TKIs trên da và móng của bệnh nhân UTPKTPN là thường gặp và phổ biến nhất ở nhóm sử dụng TKIs thế hệ 2, và ít gặp nhất ở thế hệ 3. Tác dụng phụ trên da gặp nhiều hơn trên móng. Chất lượng cuộc sống của người bệnh sử dụng TKIs thế hệ 3 tốt hơn nhóm sử dụng thế hệ 1, 2.Tyrosine Kinase inhibitors (TKIs) as the treatment for advanced-stage nonsmall cell lung cancer have been proven to be effective, improving patients’ survival with good tolerance and lower toxicity compared to chemotherapy. However, TKI therapy also has certain adverse events (AEs), notably in the skin and nails. Therefore, this study aimed to describe the AEs of TKIs on the skin and nails of NSCLC patients and to measure those patients’ quality of life. Methods: A cross-sectional study was conducted on 237 NSCLC patients who received EGFR-TKI therapy at Hanoi Oncology Hospital from March 2021 to October 2022. Evaluating skin and nail AEs based on the CTCAE 5.0, quality of life (QoL) was scored using the EROTC-QLQ30. Results: The average patients’ age is 62.62 ± 10.54 years old, the majority of them are 60 years old or older (67.5%). Dermatitis in the patient groups using the 1st, 2nd, 3rd TKI generation were 98 (55.4%)
40 (80%)
7 (35%), respectively. Paronychia were observed in 40 (22.6%), 21 (52.5%), 4 (20%) of the 1st , 2nd, 3rd TKI generation patient groups respectively. Most AEs appeared 7 to 15 days after taking TKIs. QoL scores in the respective patient groups were 73.33 (1st generation TKIs)
77.54 (2nd generation TKI)
85.43 (3rd generation TKI) Conclusions: Skin and nail AEs are common in NSCLC patients receiving TKI therapy and most common in the group using the 2nd generation of TKIs, while least common in the group using the 3rd generation. Skin AE (dermatitis) was more common than nail AE (paronychia). QoL score of the 3rd generation TKI users was higher than that of the group using the 1st, 2nd generation of TKIs. Hence, managing TKIs’ AEs and educating patients about them are important tasks of nurses.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR